ArticleCureus2026
Reduction in Wearable-Derived Maximal Oxygen Consumption (VO₂max) During Tamsulosin Use in an Endurance Athlete.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
α₁-adrenergic antagonists such as tamsulosin are widely prescribed for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. While their systemic vascular effects are well recognized, their impact on aerobic performance remains unclear. We describe a case of a competitive endurance athlete who observed a decline in wearable-derived maximal oxygen consumption (VO₂max) temporally associated with tamsulosin therapy. A male endurance runner with LUTS was initiated on treatment with tamsulosin. Subsequently, he noted an increased perceived level of exertion during training and a reduction in estimated VO₂max during activity as recorded by his smartwatch. Longitudinal running data from his device were reviewed across three consecutive time periods: prior to initiation of tamsulosin (from August 15, 2022, to March 1, 2023), during daily tamsulosin therapy (from March 1, 2023, to February 7, 2024), and following transition to daily tadalafil therapy (from February 7, 2024, to June 15, 2024). A total of 113 outdoor running sessions were included, demonstrating a decline in estimated VO₂max from baseline pre-tamsulosin (48.19 mL/kg/minute) to daily tamsulosin use (45.68 mL/kg/minute) (p = 6.42 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.